Skip to main content
. 2020 May 25;20(2):860–867. doi: 10.3892/etm.2020.8787

Figure 1.

Figure 1

Flow diagram demonstrating the number of patients at each phase of the study. R, TAP block with 0.3% ropivacaine; RD1, TAP block with ropivacaine and 0.5 µg/kg dexmedetomidine; RD2, TAP block with ropivacaine and 1 µg/kg dexmedetomidine; RD3, TAP block with ropivacaine and 2 µg/kg dexmedetomidine.